+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

A

Actively Recruiting

Metastatic colorectal cancer mCRC is a serious condition with limited treatment options after multiple therapies. Researchers are gathering detailed information on patients with mCRC who have already had at least two lines of systemic therapy. This registry aims to understand how these patients are treated and how they fare over time, collecting data from multiple cancer centers in Austria to better evaluate treatment patterns and outcomes. The study involves collecting existing medical data from patient charts, including treatment histories, test results, and imaging studies. Tumor tissue samples from deceased patients will be stored in a central biobank, and additional biological samples may be requested for specific research questions. No new diagnostic or treatment procedures are required beyond routine care. Data collection will continue until patient death or loss to follow-up. Participants involvement includes providing consent for their routine medical data to be recorded in the registry. Researchers will monitor overall survival, progression-free survival, response rates, and potential predictive biomarkers over a period of up to 10 years. Patient confidentiality is maintained by assigning unique identifiers, and no extra visits or therapies are needed beyond usual care.

Age: 18Years +All Genders
7 locations
R

Actively Recruiting

Researchers are collecting and analyzing real-world data on treatment patterns, clinical outcomes, and side effects for adult patients with advanced pancreatic ductal adenocarcinoma PDAC in Austria. This observational study focuses on individuals with locally advanced inoperable or metastatic PDAC undergoing first-line chemotherapy to better understand treatment effectiveness and toxicity in routine clinical settings. Participants receive various approved chemotherapeutic agents starting from the second line of therapy. The study includes patients treated with platinum- or gemcitabine-based chemotherapy as first-line treatment, or nal-Irinotecan5-FULeukovorin if previously treated. No experimental treatments are administered rather, researchers observe and record ongoing treatments and management strategies for PDAC. During the study, researchers systematically gather data on treatment efficacy, side effects such as neuropathy, anemia, nausea, and other adverse events, as well as treatment modifications and dose density. They also examine factors like molecular profiling and the impact of surgical interventions. Participants are followed for up to 24 months, with outcomes including the proportion receiving second-line therapy and other clinical measures. The study aims to improve understanding of real-world management and outcomes for advanced pancreatic cancer.

Age: 18Years +All Genders
14 locations
S

Actively Recruiting

Researchers are evaluating the use of Sonodyn, an investigational handheld medical device, for adults suffering from therapy-resistant myofascial pain syndrome causing low back pain, tension headache, or neck pain. This condition is a common cause of muscle pain and dysfunction, characterized by trigger points in muscles. The study is a randomized, double-blind, sham-controlled trial conducted at multiple sites in Austria and Switzerland to assess the devices impact on pain levels. The study compares active Sonodyn therapy, which delivers low-energy ultrasound, electrical, and magnetic stimulation to targeted trigger points, with a sham device that looks identical but does not deliver any stimulation. Patients undergo treatment for three weeks, activating their assigned device three times daily for 10 minutes each session. The trial includes a one-week screening phase before treatment and an eight-week follow-up period after treatment, totaling 12 weeks of participation. Participants report their average and maximum pain intensity twice daily using a Numeric Rating Scale throughout screening, treatment, and follow-up periods. They also track the use of any rescue medication. Researchers will measure pain changes as the primary outcome and assess additional factors such as medication use, quality of sleep, and quality of life. The study monitors compliance and safety while comparing results between active therapy and sham control groups.

Age: 18Years - 99YearsAll GendersPhase Not Applicable
6 locations